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Letters e21beam irradiation was administered for 11 to 18
months after onset. However, new tumors grew
outside the area of irradiation. At 18 months
after onset, the patient developed multiple ulcers
on the scalp, a 30- 3 20-mm indurated plaque on
the left cheek, marked edema of the face (Fig 1, A),
and enlargement of the involvement of multiple
cervical, mandibular, and intraparotid lymph nodes
(Fig 2, A).
Owing to the refractory nature of the tumors,
pazopanib treatment was initiated at a dose of
800 mg once daily. At day 3 of pazopanib
treatment, edema of the face began to subside,
and the patient began to open both eyes; the
edema finally disappeared by day 14. The left
cheek indurated plaque completely disappeared
(Fig 1, B). In addition, a computed tomography
scan at day 19 showed shrinking of the multiple
cervical, mandibular, and intraparotid lymph
nodes (Fig 2, B). Toxic side effects of grade 3
thrombocytopenia and grade 2 neutropenia were
apparent. Pazopanib therapy of 800 mg was
discontinued after 2 weeks and restarted at a
reduced dose of 600 mg once daily. Thereafter,
the appearance of grade 3 proteinuria required
that the dose be reduced further to 400 mg once
daily. However, partial tumor reduction has been
maintained for 26 weeks and the patient is now
undergoing a pazopanib treatment without toxic
side effects.
Pazopanib is a multi-targeted receptor tyrosine
kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3,
PDGFR-/, and c-kit.2 VEGFR-2 is up-regulated in
angiosarcoma.3 Angiosarcoma cells in the present
case were also positive for VEGFR-2, suggesting that
signals impinging on VEGFR-2 stimulate tumorigen-
esis. Accordingly, it is possible that pazopanib led to
clinical improvement by inhibiting VEGFR-2 tyrosine
kinase activity.
The administration of pazopanib results in rare
toxic effects.4 It is possible that taxane chemotherapy
contributed to these toxic effects.
Other VEGFR inhibitors (bevacizumab, sorafenib,
and sunitinib) have also been reported to be effective
treatments for angiosarcoma.1 Thus, VEGFR inhibi-
tors, such as pazopanib, may provide an additional
option for the treatment of angiosarcoma.
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Hypersensitivity to romidepsin
To the Editor: Romidepsin is a histone deacetylase
inhibitor that is FDA-approved for the treatment of
refractory cutaneous T-cell lymphoma (CTCL). It is
generally considered to be well tolerated, excluding
previously demonstrated hematologic toxicities.1 We
report a case of a hypersensitivity reaction to
romidepsin.
A 34-year-old black woman with stage IIIA CTCL
diagnosed in 2010 was started on romidepsin in April
2013 for refractory disease. Previous treatments
included psoralen with ultraviolet light A, extracor-
poreal photophoresis, interferon, bexarotene, and
doxorubicin with limited to no improvement. She
tolerated the first 2 cycles of romidepsinwell with the
initial dose administered at 10 mg/m2 and the
remaining doses at 14 mg/m2; however, she was
noted to have a low-grade fever, tachycardia,
burning sensation of her skin, and headache for 24
hours following each infusion. Immediately after
completion of the second 14-mg/m2 dose of cycle 3,
she became febrile to 39.58C, tachycardic to 150
bpm, hypotensive, and erythrodermic, necessitating
admission to the intensive care unit for emergent
resuscitation. Following stabilization and transfer to
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e22 Lettersthe general medical floor, she showed remarkable
therapeutic response to romidepsin with dramatic
resolution of thick CTCL plaques. Although our
inpatient team suspected drug reaction, she had
been started on doxycycline 100 mg twice daily for
an unrelated soft tissue infection before her
hypersensitivity event, which complicated the
clinical picture. Because of her clinical stability and
marked response to the drug, 7 days after admission,
while still an inpatient, another 14-mg/m2 infusion of
romidepsin was administered with 125 mg of
intravenous methylprednisone premedication. After
25% of the romidepsin had been infused, pruritus
and urticarial pink plaques developed, prompting its
discontinuation. Within 1 hour, the patient became
febrile to 39.58C, tachycardic to 160 bpm, hypoten-
sive, erythrodermic, and complained of skin pain.
Fluids, broad-spectrum antimicrobials for suspected
sepsis, and systemic corticosteroids were used as
supportive care, and systemic symptoms resolved
within 24 hours. Of note, all cultures during her
hospitalization were negative.
The progressive decrease in time between the
initiation of therapy and onset of symptoms,
as well as the increased severity of symptoms with
each successive infusion, is highly suggestive of
hypersensitivity to romidepsin. In retrospect, the
patient’s initial symptom of fever beginning early in
the treatment course may represent a component of
the same drug reaction that intensified with each
infusion.
Previous clinical trials have reported romidepsin
therapy to be generally well tolerated with fatigue,
nausea, vomiting, and infections as common
adverse effects.2-5 Leucopenia, granulocytopenia,
lymphopenia, thrombocytopenia, and anemia
comprise the reported hematologic side effect pro-
file.2 The death of patients in a trial of romidepsin has
also been reported, but these patients were noted to
have significant risk factors for sudden death.2 Earlier
trials, however, have not described the occurrence of
hypersensitivity reactions among the patientsstudied. Additionally, to our knowledge, there are
no previous reports of such reactions to romidepsin
in the published literature. In view of the life-
threatening reaction seen in our patient, it is
paramount to consider a hypersensitivity reaction
when a patient experiences symptoms suggestive of
an immune-mediated response, such as fever, diffuse
erythema, and/or hemodynamic changes.
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